Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept Bone Effects in Psoriatic Arthritis (ABEPSA_BB)
2017-002793-39Phase 4Terminated
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Dec 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of abatacept in psoriatic arthritis (PsA), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Change in bone erosion volume at second and third MCP joints by HR-pQCT. Started Dec 2017; status: terminated.
02
Drugs
abatacept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-002793-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002793-39.